Dario N. R. Carrara
Directeur Général chez Amzell Ltd.
Profil
Dario N.
R.
Carrara is currently the Chief Executive Officer at Amzell Ltd.
Prior to this, he worked as the Managing Director at Antares Pharma AG from 1995 to 2000, and as the Senior Vice President & MD-Pharmaceutical Group at Antares Pharma, Inc. from 1995 to 2010.
Before that, he was the Manager-Pharmaceutical Technology at Laboratorios Beta SA from 1986 to 1995.
Dr. Carrara holds a doctorate degree from Universidad de Buenos Aires.
Postes actifs de Dario N. R. Carrara
| Sociétés | Poste | Début |
|---|---|---|
Amzell Ltd.
 Amzell Ltd. Pharmaceuticals: MajorHealth Technology Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara. | Directeur Général | - |
Anciens postes connus de Dario N. R. Carrara
| Sociétés | Poste | Fin |
|---|---|---|
| ANTARES PHARMA, INC. | Corporate Officer/Principal | 31/12/2010 |
Antares Pharma AG
 Antares Pharma AG Pharmaceuticals: OtherHealth Technology Part of Halozyme Therapeutics, Inc., Antares Pharma AG manufactures and develops gel and patch technologies for use in hormone replacement therapy. Antares Pharma was acquired by Antares Pharma, Inc., a subsidiary of Halozyme Therapeutics, Inc. from Permatec Holding AG on February 01, 2001 for $13.23 million. | Corporate Officer/Principal | 01/01/2000 |
Laboratorios Beta SA
 Laboratorios Beta SA Pharmaceuticals: MajorHealth Technology Laboratorios Beta SA is an Argentinean pharmaceutical company that specializes in the manufacturing and wholesale of anti-inflammatory and anti-rheumatic drugs. The private company is based in Buenos Aires, Argentina. | Corporate Officer/Principal | 01/01/1995 |
Formation de Dario N. R. Carrara
| Universidad de Buenos Aires | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Laboratorios Beta SA
Laboratorios Beta SA Pharmaceuticals: MajorHealth Technology Laboratorios Beta SA is an Argentinean pharmaceutical company that specializes in the manufacturing and wholesale of anti-inflammatory and anti-rheumatic drugs. The private company is based in Buenos Aires, Argentina. | Health Technology |
Antares Pharma AG
Antares Pharma AG Pharmaceuticals: OtherHealth Technology Part of Halozyme Therapeutics, Inc., Antares Pharma AG manufactures and develops gel and patch technologies for use in hormone replacement therapy. Antares Pharma was acquired by Antares Pharma, Inc., a subsidiary of Halozyme Therapeutics, Inc. from Permatec Holding AG on February 01, 2001 for $13.23 million. | Health Technology |
Amzell Ltd.
Amzell Ltd. Pharmaceuticals: MajorHealth Technology Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara. | Health Technology |
